Breath Test for Breast Cancer

About Menssana Research

Menssana Research is a long-standing private diagnostics company pioneering breath-based testing for early disease detection. Its core platform analyzes volatile organic compounds (VOCs) to identify biomarkers for conditions like lung cancer, breast cancer, tuberculosis, and influenza. The company has generated a substantial body of peer-reviewed research over decades, with recent publications in 2024 focusing on breast cancer prediction, indicating active development of its pipeline toward clinical application. Menssana operates in the large and growing market for non-invasive, point-of-care diagnostics, aiming to provide rapid, low-cost screening tools.

About Breathe BioMedical

Breathe BioMedical is a private, pre-revenue diagnostics company pioneering a breath-based analytics platform for early cancer detection. Its lead program targets breast cancer, specifically as an adjunctive screening tool for women with dense breast tissue, where mammography sensitivity is low. Recent research demonstrated 88.2% accuracy in distinguishing early-stage breast cancer from controls, with density not affecting accuracy. The company is led by an experienced medtech team and is currently conducting a multi-center clinical trial to validate its technology.

Therapeutic Areas